Genmab — November 2017
-
-
Der er allerede sikkerhedsdata fra det fase 2 studie, vi talte om tidligere, og som måske kunne danne basis for en ansøgning til 1. linje godkendelse i den del der får transplantation. Der er ikke konstateret nye sikkerhedsproblemer. Studiet har iflg Genmab nu fået navnet Griffin. https://ash.confex.com/ash/2017/webprogram/Paper99989.html
-
In summary, we found daratumumab is a highly effective novel monotherapy for T-ALL in preclinical models. Based on this work, we are planning to open a multi-institutional early phase clinical trial for children and young adults with relapsed and refractory T-ALL.https://ash.confex.com/ash/2017/webprogram/Paper101472.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind